Free Email Alerts

GLP-1 Price Drop and Shortage Alerts

We track about 90 online GLP-1 programs and the FDA Drug Shortages database. When a price drops or a shortage status changes, you get a short email with what changed.

Price drop alerts

Pick this if you're price-shopping. We send an email when:

Any provider in our index drops their monthly price by 10% or more
A new lower-priced compounded program enters the index
A manufacturer (Lilly Direct, NovoCare) cuts cash-pay pricing

Shortage alerts

Pick this if you're worried about supply. We send an email when:

An FDA shortage status changes (resolved or re-listed)
FDA changes its compounding policy for GLP-1 drugs

Both at once

Most readers want both. Sign up here for both lists.

Why we built this

GLP-1 prices change often. Manufacturers run limited-time offers, and telehealth providers change their prices. Most readers don't have time to monitor about 90 provider pages and an FDA database.

So we do it. We track everything in our pricing index and our shortage tracker. When something material changes, you get a short email. Nothing else.

Sample alert

Illustrative format only. The provider and numbers below are made up.
Subject: Example Provider cut its semaglutide program to $135/mo (was $150)
Body:
Example Provider cut its semaglutide program from $150/mo to $135/mo since our last check. That's a 10% drop.
Full pricing index: clearmetabolic.com/research/glp1-cash-pay-pricing-index

What we checked

This AI-assisted public-source desk check reviewed this page's claims against our provider data and FDA's GLP-1 compounding policy page on November 4, 2026. As of that update, FDA said tirzepatide and semaglutide were not on its drug shortage list. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.

Privacy

Email goes to Buttondown (our newsletter platform). We don't sell or share. One-click unsubscribe in every email. Read our editorial policy.